INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›health›OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development
health

OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development

By Info60 World Desk•Summary of reporting by Businesswire•Sep 22, 2026•0 views•
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development
PLEASANTON, Calif.--(BUSINESS WIRE)-- #biosimilars--OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHOTM platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the SurenessTM Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar proce
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%

Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%

Businesswire

U.S. FDA Approves Update to the Label for WINREVAIRTM (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

U.S. FDA Approves Update to the Label for WINREVAIRTM (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Businesswire

Prefilled Auto Injectors Market to Reach US$ 8.63 Billion by 2035 at 13.7% CAGR; Key Players: Ypsomed, SHL Medical, and BD

Prefilled Auto Injectors Market to Reach US$ 8.63 Billion by 2035 at 13.7% CAGR; Key Players: Ypsomed, SHL Medical, and BD

Openpr.com

Fragile X Syndrome Treatment Market to Reach US$3.60 Billion by 2035 as Disease-Modifying Research Moves Beyond Symptom Management

Fragile X Syndrome Treatment Market to Reach US$3.60 Billion by 2035 as Disease-Modifying Research Moves Beyond Symptom Management

Openpr.com

Acute Otitis Media Treatment Market to Reach US$5.50 Billion by 2035 as Stewardship Reshapes Pediatric Antibiotic Demand

Acute Otitis Media Treatment Market to Reach US$5.50 Billion by 2035 as Stewardship Reshapes Pediatric Antibiotic Demand

Openpr.com

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!